Dr. Falk Pharma
CompanyGermany
Dr. Falk Pharma develops one asset, approved (ursodeoxycholic acid in primary biliary cholangitis). Mostly small molecule acting on apoptosis, lipid and ceramide metabolism and NR1H4; based in Germany.
- Assets
- 1
- Furthest
- Approved
- Trials
- 1
- Signals
- 0
Pipeline
1Bile acid that decreases intestinal cholesterol absorption and protects hepatocytes
ApprovedSmall moleculeApoptosisLipid and ceramide metabolismprimary biliary cholangitissystemic disease
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms3
- Trials3
- Similar companies6
Updated 7 Oct 2026 · 10 sources